Kenneth E. Thummel

Kenneth E. Thummel

Auto-generated profile, based on publicly available information

Kenneth E. Thummel

University of Washington

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
SLSeung‐Been Lee
Seung‐Been Lee
MWMarsha M. Wheeler
Marsha M. Wheeler
KTKenneth E. Thummel
Kenneth E. Thummel
DNDeborah A. Nickerson
Deborah A. Nickerson
Variation in the enzymatic activity of pharmacogenes is defined by star alleles (haplotypes) comprised of single‐nucleotide variants, small insertion‐deletions, and large structural variants. We recently developed Stargazer, a next‐generation sequencing‐based tool to call star alleles for the clinically important CYP2D6 gene. Here, we present the utility of extending Stargazer to call star alleles for 28 pharmacogenes using whole genome sequencing (WGS) data. We applied Stargazer to WGS data from 70 ethnically diverse samples from the Genetic Testing Reference Materials Coordination Program (GeT‐RM). These reference samples were extensively characterized by GeT‐RM using multiple pharmacogenetic testing assays. In all 28 genes, Stargazer recalled 100% of star alleles (N = 92) present in GeT‐RM's consensus genotypes (N = 1,559). Stargazer also detected star alleles not previously reported by GeT‐RM, including complex structural variants. Our results demonstrate that combining WGS data and Stargazer enables automated, accurate, and comprehensive genotyping of pharmacogenes in the human genome.

6 December 2021 in The Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
BBBert B Boyer
Bert B Boyer
SHScarlett E Hopkins
Scarlett E Hopkins
HWHoward W Wiener
Howard W Wiener
JPJonathan Q Purnell
Jonathan Q Purnell
DODiane O'Brien
Diane O'Brien
HTHemant K Tiwari
Hemant K Tiwari
The relationship between dietary n-3 PUFAs and the prevention of cardiometabolic diseases, including type 2 diabetes, is unresolved. Examination of the association between n-3 PUFAs and chronic low-grade inflammation in a population where many individuals have had an extremely high intake of marine mammals and fish throughout their lifespan may provide important clues regarding the impact of n-3 PUFAs on health. The aim of this study was to explore associations between concentrations of n-3 PUFAs resulting from habitual intake of natural food sources high in fish and marine mammals with immune biomarkers of metabolic inflammation and parameters of glucose regulation. A total of 569 Yup'ik Alaska Native adults (18–87 years old) were enrolled in this cross-sectional study between December 2016 and November 2019. The RBC nitrogen isotope ratio (NIR; 15N/14N) was used as a validated measure of n-3 PUFA intake to select 165 participant samples from the first and fourth quartiles of n-3 PUFA intakes. Outcomes included 38 pro- and anti-inflammatory cytokines and 8 measures of glucose homeostasis associated with type 2 diabetes risks. These outcomes were evaluated for their associations with direct measurements of EPA, DHA, and arachidonic acid in RBCs. Linear regression was used to detect significant relationships with cytokines and n-3 PUFAs, adiposity, and glucose-related variables. The DHA concentration in RBC membranes was inversely associated with IL-6 (β = –0.0066; P < 0.001); EPA was inversely associated with TNFα (β = –0.4925; P < 0.001); and the NIR was inversely associated with Monocyte chemoattractant protein-1 (MCP-1) (β = –0.8345; P < 0.001) and IL-10 (β = –1.2868; P < 0.001). Habitual intake of marine mammals and fish rich in n-3 PUFAs in this study population of Yup'ik Alaska Native adults is associated with reduced systemic inflammation, which may contribute to the low prevalence of diseases in which inflammation plays an important role.

1 September 1991 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
CLC A Lee
C A Lee
KTK E Thummel
K E Thummel
TKT F Kalhorn
T F Kalhorn
SNS D Nelson
S D Nelson
JSJ T Slattery
J T Slattery

1 April 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
KCKatrina G. Claw
Katrina G. Claw
LHLindsay Henderson
Lindsay Henderson
WBWylie Burke
Wylie Burke
KTKenneth E. Thummel
Kenneth E. Thummel
The integration of genomic technology into healthcare settings has the potential to transform health care through increased personalization of medical decisions. In particular, pharmacogenomic research on drug disposition and response can tailor and improve medication regimens for all patients by informing tests of function altering variation in drug metabolism and transport genes. Unfortunately, Indigenous peoples remain underrepresented in genomic and health research despite having a higher prevalence of heart disease, cancer, diabetes and stroke than any other population. Effective strategies to create research partnerships between tribal communities and genomic researchers are often lacking, yet such partnerships are needed for trustworthy research. As such, Indigenous populations are less likely to benefit from personalized medicine if they are not represented in studies that ascertain genotype‐phenotype relationships that can lead to improved drug treatment efficacy. We review what is currently known about pharmacogenetic variation in Indigenous populations and evaluate three case studies in which pharmacogenetic research with Indigenous populations were conducted. We highlight the importance of including Indigenous populations in future pharmacogenetic studies and discuss strategies for ethical engagement and collaboration in genomic research with Indigenous communities. The inclusion of Indigenous and other underrepresented communities in genomic research has the potential to expand our understanding of genomic influences on health and improve clinical approaches for all populations. Support or Funding Information NIGMS F32 GM119237 This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

1 April 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RTRakshit S. Tanna
Rakshit S. Tanna
DTDan‐Dan Tian
Dan‐Dan Tian
MMMatthew G. McDonald
Matthew G. McDonald
JCJustina Calamia
Justina Calamia
ARAllan E. Rettie
Allan E. Rettie
MPMary Paine
Mary Paine
Background: ldenseal is a botanical natural product commonly used to self‐treat the common cold and various digestive ailments. Major constituents of goldenseal include the alkaloids berberine, (−)‐hydrastine, and hydrastinine; each constituent contains a methylenedioxyphenyl ring. This structural feature can give rise to time‐dependent inhibition (TDI) of cytochromes P450 (CYPs), which may contribute to the mechanism(s) underlying reported clinical goldenseal‐drug interactions involving the CYP3A probe substrate midazolam. The aims of this work were to 1) determine the TDI kinetics of each constituent towards CYP3A activity (midazolam 1’‐hydroxylation) using human liver and intestinal microsomes (HLM, HIM), 2) apply the kinetic parameters to a mechanistic static model to predict the change in systemic exposure to oral midazolam, and 3) assess the accuracy of the prediction in healthy volunteers. Methods: IC 50 shift experiments were conducted to identify potential time‐dependent inhibitors. K I and k inact were determined using a 6 x 6 matrix of inhibitor concentrations (0.5–90 μM) and primary incubation times (0–20 min). These parameters were applied to a mechanistic static model to predict the change in midazolam area under the plasma concentration‐time curve (AUC). The pharmacokinetics of midazolam and hydroxylated metabolites were determined for 6 healthy volunteers administered a single oral dose of midazolam (2.5 mg) with a well‐characterized goldenseal product (3 g). Results: Only berberine and (−)‐hydrastine showed TDI of CYP3A activity in HLM (K I , 13–42 μM; k inact , 0.015–0.061 min −1 ) and HIM (K I , 5.4–8.5 μM; k inact , 0.040 min −1 ). Berberine additionally showed activation of CYP3A activity (up to 2‐fold compared to vehicle) at low midazolam concentrations (≤5 μM). The increase in the 1’‐ to 4‐hydroxymidazolam (1’‐OH/4‐OH) ratio with increasing berberine concentrations in both HLM and HIM (~6 to ~30) further supported activation of CYP3A activity by berberine. Berberine and (−)‐hydrastine were predicted to increase midazolam AUC by at least 6‐fold. Goldenseal increased midazolam AUC in all of the participants (1.3 to 2.2‐fold). Analysis of 1’‐OH/4‐OH partial AUC ratios did not indicate activation of CYP3A in vivo. Conclusions: The average k inact /K I ratios for berberine (1.3 mL•min −1 •μmol −1 ) and (−)‐hydrastine (4.0 mL•min −1 •μmol −1 ) were near those reported for the clinically relevant time‐dependent CYP3A inhibitors diltiazem and erythromycin (1.8–4.0 mL•min −1 •μmol −1 ), suggesting berberine and (−)‐hydrastine as candidate precipitants of the goldenseal‐midazolam interaction. Activation of CYP3A activity by berberine in vitro may have contributed to the over‐predicted midazolam AUC ratio by the static model, which only considers inhibition. Given that the half‐life for CYP3A4 is ~1–3 days, TDI of CYP3A activity in vivo by goldenseal could have persistent effects beyond cessation of consuming the natural product. Support or Funding Information National Center for Complementary and Integrative Health (U54AT008909) This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

18 May 2023 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
LZLinxi Zhu
Linxi Zhu
RSRyan Seguin
Ryan Seguin
NANathan Alade
Nathan Alade
JCJustina C. Calamia
Justina C. Calamia
KTKenneth Thummel
Kenneth Thummel
LXLibin Xu
Libin Xu
ID 53827 Poster Board 426 Benzalkonium chlorides (BACs) are a class of quaternary ammonium compounds. They are among the most common active ingredients in disinfectants used in domestic cleaning, industrial processing, and clinical settings. BACs are primarily metabolized by cytochrome P450 (CYP) enzymes through ω-hydroxylation by CYPs 4F2 and 4F11 and (ω−1)-hydroxylation (or further internal oxidation) by CYPs 2D6 and 4F12. These primary metabolites are further metabolized to ω-carboxylic acid and (ω−1)-ketone products. We hypothesize that CYP polymorphism is a major determinant of inter-individual variability in BAC persistence in humans. CYP4F2 was previously found to be an ω–hydroxylase of C16 BAC, but not of C12 BAC. In this work, we investigated the impact of CYP4F2 polymorphism (*1/*1, *3/*3, and *1/*3) on C12 and C16 BAC metabolism in 4F2-genotyped and pooled (from 10 individuals for each genotype) human liver microsomes (HLM). Wild-type (WT) (4F2*1/*1) HLM exhibited a 2.08-fold higher metabolic rate for C16 BAC than 4F2*3/*3; However, for C12 BAC, this ratio was only 1.09. The heterozygote (4F2*1/*3) HLM metabolic rates of both C12 and C16 BACs were close to WT, being 80% and 88% of the WT metabolic rates, respectively. The fraction metabolized (fm) of carboxylic acid for C16 BAC are 0.72 (*1/*1), 0.54 (*1/*3) and 0.22 (*3/*3), whereas for C12 BAC, this fm in all three variants are less than 0.05, suggesting CYP4F2 is a major contributor to the formation of ω-carboxylic acid from C16-BAC, but not C12-BAC. The use of the specific CYP2D6 inhibitor quinidine in all three groups of 4F2-genotyped HLM confirmed the significant contribution of CYP2D6 to (ω-1)-hydroxylation of both C16- and C12-BACs. Inhibition of CYP2D6 had a greater effect on C12 BAC metabolism than C16 BAC, reducing their (ω-1)-hydroxy metabolites by 67% and 55%, respectively, in WT HLM. In conclusion, the impact of 4F2*3 polymorphism on BAC metabolism in HLM was far greater for C16 BAC than for C12 BAC. Inhibition of 2D6 by quinidine was not necessary to observe this effect, indicating that the 4F2*3 polymorphism alone can substantially reduce C16 BAC metabolism in HLM. This study suggests that individuals with the CYP4F2 poor metabolizer genotype could be more susceptible to BAC exposure.